Medicated diet composition for treating heat cough, and preparation method therefor and use thereof

MYPI2025004365A0Undetermined Publication Date: 2024-07-20GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004365
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-20
Filing Date
2024-03-19
Publication Date
2024-07-20

AI Technical Summary

Technical Problem

Due to the shortage of drug resources and weak medical resources, patients with cough after novel coronavirus infection in rural areas lack effective treatment methods. The existing traditional Chinese medicine dietary therapy program fails to quickly improve the symptoms of hot cough.

Method used

The medicated dietary composition is composed of ingredients such as kumquat, water chestnut, Radix Adenophora and Platycodon grandiflorum, and is prepared by decoction. It has the effects of clearing away heat, reducing phlegm, regulating qi and relieving cough. It is suitable for use in areas with a shortage of drug resources.

Benefits of technology

The medicated dietary composition can quickly improve the symptoms of hot cough caused by the new coronavirus infection, and is especially suitable for areas with relatively scarce drug resources and relatively weak medical resources. It is convenient to obtain and easy to operate, and significantly improves the disappearance rate of cough symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025004365_DRAWING_001
    Figure PI2025004365_DRAWING_001
Patent Text Reader

Abstract

A medicated diet composition for treating a heat cough, and a preparation method therefor and use thereof are provided. The medicated diet composition for treating a heat cough includes the following raw materials in parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix, and 5-10 parts of Platycodonis radix. The medicated diet composition of the present disclosure can rapidly improve symptoms of a heat cough caused by SARS-CoV-2 infection, especially suitable for patients with the heat cough caused by SARS-CoV-2 infection in areas with relatively scarce pharmaceutical resources, limited medical facilities, or difficulties in obtaining medicine.
Need to check novelty before this filing date? Find Prior Art

Description

A medicinal diet composition for treating fever cough, and its preparation method and application Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a medicinal food composition for treating febrile cough, and a preparation method and application thereof. Background Art

[0002] Coughing is a common symptom of COVID-19 infection. Traditional Chinese Medicine (TCM) offers unique advantages in treating coughs caused by COVID-19, and a number of TCM herbal remedies are currently available. However, compared to urban areas, rural areas face a relative shortage of preventive medications, limited medical resources, and limited access to medication. Consequently, COVID-19 patients in rural areas often fail to receive timely and effective treatment, leading to further progression of their condition. Traditional Chinese Medicine (TCM) believes that "medicine and food share a common origin," equating diet with medicine. Throughout history, physicians have emphasized the role of diet in treating illnesses, in addition to medication. Dietary therapy in TCM has a deep cultural and historical heritage. Therefore, in areas with relatively limited access to medication, limited medical resources, and limited access to medication, dietary therapy using local herbs and ingredients can alleviate symptoms such as coughs caused by COVID-19. Currently, a readily available and effective dietary remedy is lacking.

[0003] Summary of the Invention

[0004] The first object of the present invention is to provide a medicinal diet composition for treating febrile cough, the second object of the present invention is to provide a method for preparing the medicinal diet composition, and the third object of the present invention is to provide an application of the medicinal diet composition.

[0005] According to a first aspect of the present invention, a medicated diet composition for treating heat cough is provided, wherein the raw materials thereof comprise, by weight, 50-100 parts of kumquat, 30-50 parts of water chestnut, 5-10 parts of northern adenophora, and 5-10 parts of platycodon.

[0006] The present invention targets fever cough caused by novel coronavirus infection, which is mainly manifested by cough, sore throat, bitter taste in the mouth, cough with yellow sputum, fever or irritability, reddish or red tongue, yellow tongue coating, floating and rapid pulse, etc.

[0007] In this formula, kumquat is warm in nature, pungent and sweet in flavor, and can regulate qi, relieve depression, and resolve food and phlegm. Water chestnut is sweet in nature and cold in nature, clearing heat, promoting fluid production, and resolving phlegm and eliminating stagnation. Together, they clear heat and resolve phlegm, regulating qi and relieving cough, and serve as the main herb. Adenophora australis is sweet and cool, nourishing lung yin, clearing lung heat, and relieving cough, assisting the main herb in clearing lung heat and resolving phlegm-heat, and serving as the assistant herb. Platycodon grandiflorum is good at promoting lung qi, relieving cough and resolving phlegm, and guiding the other herbs into the lung meridian, serving as an adjuvant. Together, these herbs clear heat and resolve phlegm, regulate qi and relieve cough, and can rapidly improve the symptoms of fever and cough associated with novel coronavirus infection.

[0008] The sources of raw materials for this recipe are as follows:

[0009] Kumquat: The fruit of Fortunella margarita (Lour.) Swingle, Rutaceae.

[0010] Water chestnut: the bulb of the water chestnut Eleocharis dulcis (Burm.f.) Trin.ex Henschel [E.tuberosa Roem et Schudt.; E.plantaginea R.Brown.] of the Cyperaceae family.

[0011] Northern Adenophora: The dried root of Glehnia littoralis Fr.Schmidt ex Miq. of the Umbelliferae family.

[0012] Platycodon: The dried root of Platycodon grandiflorum (Jacq.) A.DC., a plant of the Campanulaceae family.

[0013] In some embodiments, the medicinal diet composition for treating heat cough comprises, by weight, 100 parts of kumquat, 50 parts of water chestnut, 10 parts of northern adenophora, and 10 parts of platycodon.

[0014] In some embodiments, the medicinal diet composition for treating heat cough comprises, by weight, 50 parts of kumquat, 30 parts of water chestnut, 5 parts of northern adenophora, and 5 parts of platycodon.

[0015] In some embodiments, food-acceptable seasonings or medically acceptable excipients are also included.

[0016] According to a second aspect of the present invention, there is provided a method for preparing the above-mentioned medicinal diet composition for treating febrile cough, comprising the following steps:

[0017] Chop the water chestnuts but do not cut the kumquats, then mix the chopped water chestnuts with the kumquats, Glehnia littoralis and Platycodon grandiflorum, add 2-5 times the weight of water and boil for 30-60 minutes to obtain the product.

[0018] The present invention does not cut the kumquat when preparing the medicinal food composition, thereby being able to more effectively boil the effective ingredients in the kumquat peel and pulp, making the medicinal food taste sweet and sour, and not only being able to focus on relieving cough and reducing phlegm, but also being able to better cooperate with other ingredients to exert the therapeutic effects of clearing away heat and reducing phlegm, regulating qi and relieving cough.

[0019] According to a third aspect of the present invention, there is provided the use of the above-mentioned medicinal diet composition for treating febrile cough in the preparation of a medicament for treating novel coronavirus infection.

[0020] According to a fourth aspect of the present invention, there is provided the use of the above-mentioned medicinal diet composition for treating fever cough in the preparation of a medicine for treating cough caused by novel coronavirus infection, accompanied by sore throat or coughing up yellow sputum.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] (1) The medicinal food composition of the present invention can quickly improve the symptoms of fever and cough caused by novel coronavirus infection, and is particularly suitable for patients with fever and cough caused by novel coronavirus infection in areas where drug resources are relatively scarce, medical resources are relatively weak, and it is relatively difficult to purchase medicines.

[0023] (2) The present invention selects four substances that are both food and Chinese medicinal materials to form a medicinal diet composition, selects kumquat and water chestnut, which are common ingredients on the market, as the main medicine, and combines them with common Chinese medicinal materials on the market that are both medicinal and edible, such as northern adenophora and platycodon. The ingredients are convenient to obtain, easy to operate, delicious and inexpensive, providing a feasible medication option for patients with fever and cough after infection with the new coronavirus. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] FIG1 is a graph showing the survival curves of two groups after PSM matching in the clinical trial of the present invention. DETAILED DESCRIPTION

[0025] The present invention will be further described in detail below in conjunction with specific examples. It is worth noting that the following examples are only for better explanation of the present invention and are not intended to limit the scope of protection of the present invention. The undisclosed process steps in the examples are prior art. Unless otherwise specified, the following raw materials are commercially available.

[0026] Example 1

[0027] The medicinal diet for treating heat cough of this embodiment comprises the following raw materials in parts by mass: 100 g kumquat, 50 g water chestnut, 10 g northern adenophora, and 10 g platycodon.

[0028] The preparation method comprises the following steps:

[0029] Chop the water chestnuts into small pieces, but do not cut the kumquats. Then mix the chopped water chestnuts with kumquats, Glehnia littoralis, and Platycodon grandiflorum, add to 500mL of water, and boil for 40 minutes until the volume reaches 200mL.

[0030] The medicated diet prepared in this embodiment is suitable for adult patients with fever and cough caused by novel coronavirus infection. The dosage of one dose is 200 mL, and one dose is taken once a day, divided into 3-4 doses.

[0031] Example 2

[0032] The medicinal diet for treating heat cough of this embodiment comprises the following raw materials in parts by mass: 50 g of kumquat, 30 g of water chestnut, 5 g of northern adenophora, and 5 g of platycodon.

[0033] The preparation method comprises the following steps:

[0034] Chop the water chestnuts into small pieces, but do not cut the kumquats. Then mix the chopped water chestnuts with kumquats, Glehnia littoralis, and Platycodon grandiflorum, add to 300mL of water, and boil for 40 minutes until the total volume reaches 150mL.

[0035] The medicated diet prepared in this embodiment is suitable for children with fever and cough caused by novel coronavirus infection. The dosage of one dose is 150 mL, and one dose is taken once a day, divided into 3-4 doses.

[0036] Next, to illustrate the therapeutic effect of the medicinal diet composition of the present invention on fever and cough caused by novel coronavirus infection, clinical trials were conducted using the medicinal diet prepared in Examples 1-2.

[0037] 1. Relevant standards

[0038] (1) Diagnostic criteria

[0039] 1. Western medicine disease diagnosis

[0040] Refer to the "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Ninth Edition)", there is an epidemiological history and clinical manifestations, and it meets the etiological evidence (positive novel coronavirus nucleic acid test or positive antigen test).

[0041] The disease is classified into mild and common types according to the "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Ninth Edition)".

[0042] 2. Diagnostic criteria for TCM syndromes

[0043] Hot cough: cough and sore throat, bitter taste in the mouth with yellow phlegm, fever or irritability, red tongue or red tongue, yellow tongue coating, and floating and rapid pulse.

[0044] Cold cough: cough with itchy throat, white phlegm, fear of cold, white or greasy tongue, floating and tight pulse, accompanied by headache, clear runny nose, cold and painful limbs.

[0045] (2) Inclusion criteria

[0046] 1. Those who test positive for novel coronavirus nucleic acid or antigen;

[0047] 2. According to the diagnostic criteria of the "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial 9th ​​Edition)", the clinical type is mild or common;

[0048] 3. Cough as the main symptom;

[0049] 4. The patient or his / her legal representative signs the informed consent form.

[0050] (3) Exclusion criteria

[0051] 1. People with allergies or those who are allergic to the medicinal taste of the medicinal diet composition of the present invention;

[0052] 2. Patients with chronic lung diseases such as bronchiectasis, bronchopneumonia, chronic lung abscess, chronic cough for more than 8 weeks, chronic pharyngitis with cough, lung cancer, respiratory bacterial infection, etc., which may affect the judgment of cough symptoms;

[0053] 3. Heavy smokers (years of smoking × number of cigarettes smoked per day ≥ 400, such as smoking history ≥ 20 years, ≥ 20 cigarettes per day);

[0054] 4. Unable to cooperate with the follow-up;

[0055] 5. Pregnant female subjects;

[0056] 6. Patients with severe underlying diseases or acute exacerbation of chronic diseases, such as acute heart failure;

[0057] 7. Participants in or currently participating in other clinical trials within one month before this study.

[0058] 2. Case Sources and Grouping

[0059] The cases came from patients infected with the new coronavirus in Yangshuo Town, Baisha Town, Fuli Town, Gaotian Town, and Puyi Township, Yangshuo County, Guangxi.

[0060] The experiment was based on a real-world observational study design, with an experimental group: control group ratio of 2:1; with a two-sided α=0.05 and β=0.10, that is, at a test level of 0.05 and a confidence level of 90%, 483 cases were required in the experimental group and 242 cases in the control group; considering a 15% loss to follow-up rate, 555 cases were required in the experimental group and 278 cases were required in the control group, for a total of 833 samples.

[0061] 3. Observation Indicators and Timing

[0062] (1) General information, including age, gender, height, weight, past medical history, onset time, whether or not COVID-19 vaccine was received, smoking history, etc., was collected during the first observation.

[0063] (2) Clinical symptoms and signs: including fever, cough, shortness of breath, sore throat, diarrhea, nasal congestion and runny nose, fatigue, poor appetite, headache, muscle pain, chest tightness, chest pain, loss of taste, loss of smell, etc.; collected every day during treatment.

[0064] (3) Cough severity score sheet, as shown in Table 1, was collected daily during the treatment period. The treatment period was 5 days, and patients whose cough symptoms disappeared during the first 5 days were followed up on the 6th and 7th days.

[0065] Table 1 Cough severity score table

[0066] (4) Treatment plan, including whether to use other drugs for the treatment of novel coronavirus infection or symptomatic treatment.

[0067] (5) Conditions after taking the medicine, collected every day during the treatment period.

[0068] IV. Treatment Plan

[0069] 1. Conventional treatment plan: Refer to the "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Ninth Edition)" for diagnosis and treatment, including symptomatic antipyretic, analgesic, and anti-vomiting measures.

[0070] 2. Treatment plan based on TCM syndrome differentiation:

[0071] (1) Cold cough: Adults: Add 100g kumquat, 20g ginger, 3g tangerine peel, 10g platycodon grandiflorum to 500ml of water, decoct for 40 minutes until the volume is reduced to 200ml. The dosage is 200ml. Take one dose per day, divided into 3-4 times. Children: Add 50g kumquat, 10g ginger, 2g tangerine peel, 5g platycodon grandiflorum to 300ml of water, decoct for 40 minutes until the volume is reduced to 150ml. The dosage is 150ml. Take one dose per day, divided into 3-4 times. The treatment period is 5 days.

[0072] (2) Heat cough: Adult patients took the medicated diet prepared in Example 1, with a dosage of 200 ml, once a day, divided into 3-4 doses. Children took the medicated diet prepared in Example 2, with a dosage of 150 ml, once a day, divided into 3-4 doses. The treatment period was 5 days.

[0073] In principle, patients who adopt TCM syndrome differentiation and treatment plan should not take other Chinese medicines for cough and phlegm.

[0074] Patients in the control group received conventional treatment, while those in the experimental group received Traditional Chinese Medicine (TCM)-based treatment. Patients were assigned to either the control or experimental group based on the treatment regimen they received, and efficacy indicators were compared between the groups. The primary efficacy indicator was the time it took for cough symptoms to disappear.

[0075] 5. Statistical Methods

[0076] All data were analyzed using SPSS and R. Normally distributed data were expressed as mean ± standard deviation, and intergroup comparisons were performed using t-tests or analysis of variance. Nonnormally distributed data were analyzed using nonparametric tests. Categorical variables were expressed as numbers and percentages, and intergroup comparisons were performed using the chi-square test or the exact probability method. Propensity score matching and Cox regression analysis were used to compare the time to resolution of cough symptoms between the two groups. Propensity score matching was performed using nearest neighbor matching, with a caliper value of 0.2. A P value of < 0.05 was considered statistically significant.

[0077] 6. Test Results

[0078] A total of 1,434 patients were followed up. After excluding patients without cough at baseline (627 patients), those with concurrent chronic lung disease (13 patients), and those who were heavy smokers (30 patients), a total of 763 patients were included, including 282 in the control group and 481 in the experimental group. In the experimental group, 204 patients had a fever cough and 225 had a cold cough. Fifty-two patients had no record of either a cold cough or a fever cough and were not included in the analysis.

[0079] To illustrate the therapeutic effect of the medicinal diet composition of the present invention on fever cough caused by novel coronavirus infection, patients with fever cough were divided into a medicinal diet composition group, and then the control group and the medicinal diet composition group were analyzed as follows:

[0080] 1. Baseline analysis

[0081] The baseline information of the patients is shown in Table 2.

[0082] Table 2 Baseline comparison between the control group and the medicinal diet composition group

[0083] Note: Follow-up time = last follow-up date - baseline form completion date.

[0084] As can be seen from Table 2, the median follow-up time was 7 days. Patients in the medicinal diet composition group had a longer cough duration when they were enrolled, and there were more smoking patients. The difference between the two groups was statistically significant (P < 0.05).

[0085] 2. Comparison of the two groups before and after propensity score matching

[0086] Propensity score matching was performed based on age, gender, presence of underlying diseases, time from first cough to enrollment, number of vaccinations, smoking status, use of cough suppressants before enrollment, and cough symptom score before enrollment. After matching, the two groups each had 178 cases, and the two groups were balanced and comparable except for the number of vaccinations. The comparison results of the two groups after propensity score matching are shown in Table 3:

[0087] Table 3 Comparison of the two groups after propensity score matching

[0088] Note: SMD, standardized mean difference. SMD < 0.1 indicates that the two groups are balanced and comparable.

[0089] 3. Comparison of results after matching

[0090] The regression analysis after propensity score matching between the two groups is shown in Table 4:

[0091] Table 4 Regression analysis after propensity score matching between the two groups

[0092] Notes: (1) HR: Hazard ratio. HR>1 indicates that the medicinal diet composition group is more likely to have the cough symptom disappear than the control group.

[0093] (2) Definition of cough disappearance: For patients with a total score of >5 on the cough severity rating scale shown in Table 1, the date from the first dose to the first time a score of 5 on the cough severity rating scale shown in Table 1 appears after the dose;

[0094] (3) *Since vaccination was not fully matched, the matched data were used to adjust for the confounding factor of the number of vaccinations.

[0095] As can be seen from Table 4, after a median follow-up of 7 days for both groups of patients, the disappearance of cough symptoms in the medicinal diet composition group was 1.32 (1.02, 1.71) times that of the control group.

[0096] 4. Survival curves of the two groups after matching

[0097] In the matched database, propensity score matching (PSM) was performed with cough as the dependent variable and group information as the independent variable. Kaplan-Meier survival curves were drawn in R (v.3.3.2), and the log-rank method was used to compare the differences between the two groups.

[0098] The survival curves of the two groups after matching are shown in FIG1 . As can be seen from FIG1 , the cough symptoms of the medicinal diet composition group disappeared faster.

[0099] 5. Comparison of secondary indicators between the two groups after propensity score matching

[0100] The comparison results of the secondary indicators of the two groups after propensity score matching are shown in Table 5:

[0101] Table 5 Comparison of secondary indicators between the two groups after propensity score matching

[0102] Notes: (1) CET: Cough Evaluation Test score, scored according to Table 1;

[0103] (2) There were cases of loss to follow-up on the 3rd and 5th days, so the number of follow-up on the 3rd and 5th days was less than 178. The cough symptom disappearance rate on the 3rd day was a = 77 / 158 = 48.7%; b = 58 / 162 = 35.8%; the cough symptom disappearance rate on the 5th day was c = 80 / 160 = 50%; d = 87 / 139 = 62.6%;

[0104] (3) The treatment period was 5 days. Patients filled out the CET score sheet every day during the treatment. Patients whose cough symptoms disappeared in the first 5 days were followed up on the 6th and 7th days. Therefore, the number of patients followed up on the 7th day was less than 178. The cough symptom disappearance rate on the 7th day was e = 39 / 96 = 40.6%; f = 83 / 89 = 93.3%.

[0105] As can be seen from Table 5, on the third day of medication, the cough symptom disappearance rate in the control group was higher, and the difference was statistically significant (35.8% in the medicinal diet composition group vs. 48.7% in the control group, P = 0.019); on the fifth day after medication, the cough symptom disappearance rate in the medicinal diet composition group was higher than that in the control group (62.6% in the medicinal diet composition group vs. 50% in the control group, P = 0.029); on the seventh day after medication, the cough symptom disappearance rate in the medicinal diet composition group was higher than that in the control group (93.3% in the medicinal diet composition group vs. 40.6% in the control group, P < 0.001).

[0106] 6. Conclusion

[0107] After taking the medicated diet composition of the present invention, the disappearance rate of cough symptoms in patients with fever and cough caused by the novel coronavirus infection was 1.32 (1.02, 1.71) times that of the control group (median follow-up was 7 days). 5 days and 7 days after taking the medicated diet composition of the present invention, the disappearance rate of cough symptoms in patients with fever and cough caused by the novel coronavirus infection was higher than that in the control group, and the difference was statistically significant. This shows that the medicated diet composition of the present invention can significantly improve the symptoms of fever and cough caused by the novel coronavirus infection.

[0108] The above descriptions are only some specific embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, and these all fall within the scope of protection of the present invention.

Claims

1. A medicinal diet composition for improving fever and cough caused by novel coronavirus infection, characterized in that: The raw material composition is as follows by weight: 50-100 parts of kumquat, 30-50 parts of water chestnut, 5-10 parts of northern adenophora, and 5-10 parts of platycodon.

2. The medicinal diet composition for improving fever and cough caused by novel coronavirus infection according to claim 1, characterized in that: The raw material composition is as follows by weight: 100 parts of kumquat, 50 parts of water chestnut, 10 parts of northern adenophora, and 10 parts of platycodon.

3. The medicinal diet composition for improving fever and cough caused by novel coronavirus infection according to claim 1, characterized in that: The raw material composition is as follows by weight: 50 parts of kumquat, 30 parts of water chestnut, 5 parts of northern adenophora, and 5 parts of platycodon.

4. The medicinal diet composition for improving fever and cough caused by novel coronavirus infection according to any one of claims 1 to 3, characterized in that: Food-acceptable seasonings or medically acceptable auxiliary materials may also be added.

5. The method for preparing the medicinal diet composition for improving fever cough caused by novel coronavirus infection according to any one of claims 1 to 4, characterized in that: The following steps are involved: Chop the water chestnut into pieces, but do not cut the kumquat. Then mix the chopped water chestnut with kumquat, Glehnia littoralis and Platycodon grandiflorum, add into 2-5 times the weight of water and boil for 30-60 minutes to obtain the product.

6. Use of the medicinal diet composition for improving fever cough caused by novel coronavirus infection as described in any one of claims 1 to 4 in the preparation of a medicine for improving fever cough caused by novel coronavirus infection, accompanied by sore throat or coughing up yellow sputum.